These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 23562625

  • 1. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
    Irwin N, Franklin ZJ, O'Harte FP.
    Eur J Pharmacol; 2013 Jun 05; 709(1-3):43-51. PubMed ID: 23562625
    [Abstract] [Full Text] [Related]

  • 2. Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists.
    O'Harte FP, Franklin ZJ, Rafferty EP, Irwin N.
    Mol Cell Endocrinol; 2013 Dec 05; 381(1-2):26-34. PubMed ID: 23891841
    [Abstract] [Full Text] [Related]

  • 3. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
    O'Harte FP, Franklin ZJ, Irwin N.
    Diabetes Obes Metab; 2014 Dec 05; 16(12):1214-22. PubMed ID: 25060150
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM, Irwin N, O'Flynn D, Franklin ZJ, Hewage CM, O'Harte FP.
    J Endocrinol; 2016 Jun 05; 229(3):319-30. PubMed ID: 27098830
    [Abstract] [Full Text] [Related]

  • 6. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR.
    Biol Chem; 2004 Feb 05; 385(2):169-77. PubMed ID: 15101559
    [Abstract] [Full Text] [Related]

  • 7. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP, Ng MT, Lynch AM, Conlon JM, Flatt PR.
    Mol Cell Endocrinol; 2016 Aug 15; 431():133-44. PubMed ID: 27179756
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The glucagon receptor antagonist desHis1Pro4Glu9-glucagon(Lys12PAL) alters alpha-cell turnover and lineage in mice, but does not cause alpha-cell hyperplasia.
    Lafferty R, Tanday N, Dubey V, Coulter-Parkhill A, Vishal K, Moffett C, O'Harte F, Flatt PR, Irwin N.
    Mol Cell Endocrinol; 2023 Jun 15; 570():111932. PubMed ID: 37080378
    [Abstract] [Full Text] [Related]

  • 10. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM, Pathak N, Flatt YE, Gault VA, O'Harte FP, Irwin N, Flatt PR.
    Eur J Pharmacol; 2014 Nov 15; 743():69-78. PubMed ID: 25246014
    [Abstract] [Full Text] [Related]

  • 11. Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice.
    Franklin ZJ, O'Harte FP, Irwin N.
    Biol Chem; 2014 Apr 15; 395(4):433-42. PubMed ID: 24200535
    [Abstract] [Full Text] [Related]

  • 12. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.
    Biol Chem; 2003 Dec 15; 384(12):1543-51. PubMed ID: 14719796
    [Abstract] [Full Text] [Related]

  • 13. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD, Flatt PR, Gault VA.
    Biochem Pharmacol; 2010 Dec 01; 80(11):1727-35. PubMed ID: 20735990
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
    Lynch AM, Pathak N, Pathak V, O'Harte FP, Flatt PR, Irwin N, Gault VA.
    Diabetologia; 2014 Sep 01; 57(9):1927-36. PubMed ID: 24962667
    [Abstract] [Full Text] [Related]

  • 19. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
    Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.
    J Mol Endocrinol; 2003 Dec 01; 31(3):529-40. PubMed ID: 14664713
    [Abstract] [Full Text] [Related]

  • 20. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
    O'Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR.
    Am J Physiol Endocrinol Metab; 2007 Jun 01; 292(6):E1674-82. PubMed ID: 17299087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.